Sonodynamic therapy using MRI-guided focused ultrasound in combination with 5-aminolevulinic acid to treat recurrent glioblastoma multiforme
Active Project Grant Awarded Last action
- Award ID
- R44CA275508
- Recipient
-
Sonalasense, Inc. UEI LC3GHFGF2KK1
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,185,843
Award facts
- Assistance listing
- 93.394 Cancer Detection and Diagnosis Research
- Completion date 80% complete
- Originally
- Place of performance
- Berkeley, CA 94710, USA
Award details come from USAspending.gov.
Description
- Abstract
- Glioblastoma multiforme (GBM) is a rare and deadly cancer. First line treatment for GBM includes maximal surgical resection with radiotherapy administered post-surgery, and concomitant administration of adjuvant temozolomide. Tumor recurrence is nearly inevitable due to the microscopic, infiltrating cells that are found centimeters from the margin of visible tumor mass. There is currently no effective standard of care for recurrent (rgbm) and this highly aggressive disease leads to death within 15 months after diagnosis and has a 5-year survival rate of
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $796,215 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $694,814 | |
| Original award | $694,814 |
Quick answers
Who received award R44CA275508?
R44CA275508 was awarded to Sonalasense, Inc. by National Cancer Institute (National Institutes of Health) on April 1, 2023.
How much is award R44CA275508 worth?
$2,185,843 has been obligated on R44CA275508.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award